Biography

Ward Mosmuller studied Molecular Sciences at Wageningen University and obtained his PhD-degree in 1993 in Bio-organic Chemistry. He then joined Senter, the Dutch agency for technology and innovation; a.o. he was coordinator of the national innovation programme on (bio)catalysis and manager of the industrial development loan scheme withy a € 700 million project portfolio. During this period he obtained his MBA-degree.                                   

In 2001 he joined PricewaterhouseCoopers, Global Risk Management Solutions; he was one of the key members of the Life Sciences team of PwC. At the end of 2002 he became managing director of the BioPartner Network, an organisation with the aim to improve entrepreneurship in life sciences especially at universities.

In 2005 he started his own consultancy company SCILS, with a focus on innovation and technology transfer; he was one of the founders of Health Valley. In 2006 he was cofounder of the Technology Transfer Office of VU University & Medical Centre and was appointed as director on a part-time basis.

In March 2009 he joined DSM as director corporate public affairs.

Abstract presentation
From fossil to "biobased": the next transition of DSM?
We face a series of challenges -including climate change, resource scarcity, population growth and increased income driven consumption - which have fundamentally undermined the long-term viability of our fossil carbon based economic models and societies, and will drive the development of the bio-based economy. A transition towards an economy that uses bio carbon sources like sugars, plant waste and special grown crops while at the same time fossil carbon sources based production will remain fundamental to the global economy in the foreseeable future. DSM is committed to play a leading role in the transition to the bio-based economy.
What are the challenges that we face? How can DSM use its expertise in Materials Sciences and Life Sciences to help develop the more sustainable bio-based technology and processes? How has DSM already contributed to the building of a bio based economy? And what's the business rational behind it?
Ward Mosmuller will elaborate on DSM's views, the opportunities and the innovationsand share some of DSM's best practices.